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ABSTRACT 
 
Objective: Neoadjuvant chemoradiotherapy has considered one of the standard 
treatment modalities for locally advanced rectal cancers. Chemoradiotherapy 
has a variety of different effects and responses on tumor, tumor bed and 
peritumoral tissues. The purpose of the present study was to evaluate the 
stromal responses in tumor bed between the different treatment modalities and 
different clinical T stages.  
Methods: Fifty-seven consecutive patients with median age of 62.4 years were 
treated for rectal adenocarcinoma between January 2005 and July 2012 in 
Uludağ University Medical Faculty. Twenty-three of the patients were treated 
with neoadjuvant chemoradiation therapy and following surgery, 34 patients 
treated with surgery only. 
Results: When we compared the stromal responses in the tumor bed between 
the two different treatment modalities, the amount of fibrosis and intensity of 
inflammatory cell infiltration were found considerably marked. The existence of 
calcification, hemosiderin-laden macrophages and mucin lakes were found also 
significant marked. There was no difference found in between the patients with 
different clinical stages which were received neoadjuvant CRT.  
Conclusion: The stromal response in the tumor bed increases with the 
neoadjuvant chemoradiotherapy but the excess of the response doesn’t have 
any relation with the clinical T stage.  
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ÖZET 
 
Amaç: Neoadjuvant kemoradyoterapi lokal ileri rektal kanserlerdeki standart 
tedavi seçeneklerinden biridir. Kemoradyoterapi tümöral dokularda ve çevre 
dokularda çok çeşitli değişikliklere ve cevaplara neden olmaktadır. Bu çalışmanın 
amacı farklı tedavi seçeneklerinin tümör yatağında yarattığı değişiklikleri 
incelemektir. 
Gereç ve Yöntemler: Uludağ Üniversitesi'nde Ocak 2005-Temmuz 2012 arasında 
rektal adenokarsinom nedeniyle tedavi edilmiş, ortalama yaşları 62.4 olan 57 
hasta değerlendirildi. Hastaların 23 tanesi pre-operatif kemoradyoterapi sonrası 
cerrahi rezeksiyon yapılan, 34 tanesi ise sadece cerrahi rezeksiyon yapılan 
hastalardı. 
Bulgular: Tümör yatağında stromal yanıtlar, neoadjuvant kemoradyoterapi 
sonrası cerrahi rezeksiyon yapılan hastalar ile sadece cerrahi rezeksiyon yapılan 
hastalar arasında değerlendirildiğinde, fibrozis ve inflamatuvar hücre 
infiltrasyonu açısından istatistiksel olarak anlamlı farklar bulundu. Kalsifikasyon, 
hemosiderin yüklü makrofajlar ve müsin gölcüklerinin varlığı açısından da belirgin 
farklar saptandı. Neoadjuvant kemoradyoterapi alan hasta grubunda, klinik T 
evreleri arasında değişkenler açısından fark mevcut değildi. 
Sonuç: Tümör yatağındaki stromal cevap neoadjuvant kemoradyoterapi ile artış 
göstermektedir ancak bu artmış yanıtın tümör evresi ile ilişkisi saptanmamıştır. 
 
 
 
Anahtar Sözcükler: Rektum, adenokarsinom, neoadjuvant kemoradyoterapi, 
stromal yanıt, T evresi, tümör yatağı 
 
Geliş Tarihi:     09.03.2017              Kabul Tarihi: 05.09.2017 
 
 
 
 
 
 
 
 
 
 
 
235 Original Investigation / Özgün Araştırma 
 
 
 
 
INTRODUCTION 
 
Rectal cancer is the third most frequent malignancy in males and second in 
females, accounting for about 1.2 million new cases per year worldwide (1).  
Neoadjuvant treatment has become the standard of care for locally advanced 
gastrointestinal tumors (2). The modern treatment of rectal cancer needs a 
multidisciplinary approach and a cooperative effort between the medical 
departments (3).  Based on the randomized clinical trials, neoadjuvant 
chemoradiotherapy (CRT) followed by surgery is established as the standard 
treatment in locally advanced rectal tumor including clinically T3/T4 and/or 
clinically node positive stage cancers (4). It has been demonstrated in several 
studies, however, that clinical outcome depends not only on the initial stage of 
the tumor, but also on the CRT-induced tumor response which varies among 
individual patients (1). The purpose of the neoadjuvant CRT are both downsizing 
and downstaging the tumor. Downsizing the tumor fascilitates the surgical 
resection, enables sphincter-preserving procedure and improve local control (5).   
A growing body of evidence indicates that pathological response to 
neoadjuvant treatment can be measured with the histopathological tumor 
regression grade (TRG) (6). Rectal cancers that respond to neoadjuvant 
treatment undergo significant changes, which may result in complete 
disappearance of carcinoma cells and replacement of the tumor by fibrous or 
fibroinflammatory tissue (7).  
Neoadjuvant chemoradiation therapy in rectal cancer is associated with 
significant tumor response and downstaging. Several systems for tumor 
response have been advocated (8,9), and a modified Ryan scheme is suggested, 
which has been shown to provide good inter-observer reproducibility provide 
prognostic significance (10). 
According to the CAP protocol for the examination of specimens from patients 
with primary carcinoma of the colon and rectum, the tumor regression score 
(TRS) was established as follows: Score 0: No viable cancer cells (complete 
response), Score 1: Single cells or rare small groups of cancer cells (near complete 
response), Score 2: Residual cancer with evident tumor regression, but more 
than single cells or rare small groups of cancer cells (partial response), Score 3: 
Extensive residual cancer with no evident tumor regression (poor or no 
response) (11). 
The aim of this study is to find out the stromal responses in the tumor bed 
between the different treatment modalities and between the different clinical T 
stages.  
 
MATERIALS and METHODS 
 
Patients 
A total of 57 consecutive patients were treated for rectal adenocarcinoma 
between January 2005 and July 2012 at Uludağ University. The patients were 
selected retrospectively from the pathology archive. The mean age of 57 patients 
was 62,4±12,2 (range, 28-81 years). Pre-treatment workup consisted of digital 
rectal examination, rectosigmoidoscopy, biopsy, abdominopelvic computed 
tomography and chest X-ray. All the 57 patients were categorized according to 
the pre-treatment clinical T stage. 
Twenty-three of the patients were treated with pre-operative CRT and surgery, 
while the remaining 34 patients treated with surgery only. In all patients which 
treated with neoadjuvant CRT, 3D planned conformal radiotherapy was carried 
out with belly board. Primary tumor as well as lymph nodes at risk was covered 
and received 45 Gy in 25 fractions over a period of 5 weeks. As a concomitant 
chemotherapy 500 mg/m2 5-flourourasil continuous infusion was administered. 
Surgical resection was performed 6-9 weeks after the completion of the CRT. The 
main demographic data of all patients is given in Table 1. The remaining 34 
patients treated with surgery only had chosen as a control group. 
 
Histopathological evaluation 
Pathological response to neoadjuvant CRT in the tumor bed was determined 
by histopathological evaluation of resected specimens. Evaluation of the TRS, 
modified Ryan scheme was used. 
To assess the stromal responses in tumor bed, we evaluated fibrosis and 
inflammatory cell infiltration around the tumor islands and within the tumor bed. 
Intensity of fibrosis (Figure 1) and presence of inflammatory cells (Figure 2) were 
classified as low (Grade 1), intermediate (Grade 2), and high (Grade 3). While 
evaluating the inflammatory cells, we counted both the lymphocytes and the 
polymorphonuclear leukocytes. Other variables that we noted while evaluating 
the changes in the tumor bed were occurrence of calcification, hemosiderin-
laden macrophages, and mucin lakes. 
 
Figure 1: Grading the desmoplastic stromal response based on the amount of the collagen around the tumor islands; a) Grade 1 (H&E x40), b) Grade 2 (H&E x40), c) Grade 
3 (H&E x25).  
 
Figure 2: Grading the inflammatory response based on the intensity of the inflammatory cells; a) Grade 1 (H&E x40), b) Grade 2 (H&E x100), c) Grade 3 (H&E x40).  
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Statistical analysis 
Statistical analysis was performed with SPSS statistical software for Windows, 
version 13.0 (SPSS Inc, Chicago, IL, USA). Differences between groups were 
analyzed using Student T-test for continuous variables. ANOVA test was used to 
test the difference between radiotherapy group. The normality of data was 
checked before the statistical analysis was performed. A P value of less than 0.05 
was considered to be whereas statistically significant.  
 
RESULTS 
 
Low anterior resection or very low anterior resection were performed to all 
patients. There were 23 patients treated with neoadjuvant CRT and surgery 
(Group 1), while other 34 patients treated with surgery only (Group 2). Patients 
clinically staged before treatment. In Group 1, 4 patients were found cT2, 15 
patients cT3, 4 patients cT4, respectively. In Group 2, 7 patients were found cT2, 
21 patients cT3, 6 patients cT4, respectively. Pathological evaluation of the rectum 
resections, response to neoadjuvant CRT revealed complete response (TRS 0) in 
4, near complete response (TRS 1) in 7, partial response (TRS 2) in 8 and, poor or 
no response (TRS 3) in 4 of 23 patients.  
As shown in Table 2, the intensity of fibrosis and inflammatory cell infiltration 
in the tumor bed were found significantly marked in Group 1 (p<0.01). The 
occurrence of calcification, hemosiderin-laden macrophages and mucin lakes in 
the tumor bed were also found significantly distinctive in Group 1 (p<0.01). 
We evaluated the same variables between different clinical T stages in Group 
1.  There were no differences found in stromal responses between different 
clinical stages (Table 3). 
 
Table 1: The main demographic data of the patients. 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Neoadjuvant CRT is indicated for all or almost all patients with cT3/cT4 rectal 
cancer determined either by trans rectal ultrasound (TRUS) or magnetic resonans 
imaging (MRI). Relative indications for neoadjuvant CRT include the presence of 
clinically node-positive rectal cancer in a patient with an MRI or TRUS staged 
T1/T2 rectal cancer (12). Physical examination, endoscopy, and imaging are used 
to define local tumor characteristics and to identify distant disease. Although 
conventional computed tomography is accurate in identifying invasion of 
neighboring structures, it is not able to demonstrate the layers of the rectal wall 
accurately. Investigations currently best suited for the determination of T 
classification and N status are EUS and MRI (3). In our institution, pretreatment 
rectal cancer staging was done with computed tomography evaluation. The main 
deficiency of this study was pretreatment clinical staging that evaluated by using 
the computed tomography images only.   
 
Table 2: Stromal response variables between the two different treatment 
modalities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is very well known that the CRT has effects on both the tumor itself and the 
stroma also. Stromal changes include fibrosis, inflammation, mucin lakes 
(without tumor cells) and the presence of hemosiderin-laden macrophages. 
Calcification of the necrotic tumor cells can also be seen (12). In our study, all of 
the stromal changes were seen in both Group 1 and Group 2. Although 
desmoplastic stromal response, inflammatory cell infiltration, calcification and 
mucin lakes can be seen against to the tumor development but disappearance 
of tumor cells, replacement of the tumor by the fibrous tissue and hemosiderin-
laden macrophages are changes that related with the CRT (7). In our study, 
desmoplastic stromal response and the inflammatory cell response were found 
significantly marked around tumor areas and in the tumor bed in Group 1. 
Calcification and mucin lakes were also found pronounced in the same patient 
group. In our study, there was no evidence of hemosiderin-laden macrophages 
in Group 2. We thought that this finding also supports the evidence of the CRT 
related findings. Occurrence of hemosiderin-laden macrophages is very helpful 
to find the tumor bed especially the tumor is totally disappeared because of the 
neoadjuvant treatment (13).  
 
Table 3: Stromal response variables between the neoadjuvant CRT received cT2, 
cT3, and cT4 groups. 
Treatment prosedure Age Sex Clinical T Stage Total (n) 
 mean Male Female cT2 cT3 cT4  
nCRT + Surgery (Group 1) 59,7±14,1 12 11 4 15 4 23 
Surgery only     (Group 2) 64,2±10,6 26 8 7 21 6 34 
 Neoadjuvant 
CRT + Surgery  
(Group 1) 
Surgery 
only 
(Group 2) 
p 
n 23 34  
Fibrosis 
0 0 3 
0,000 1 2 14 2 10 15 
3 11 2 
Inflamatory cell infiltration 
0 0 1 
0,010 1 7 17 2 6 12 
3 10 4 
Calcification 
0 12 31 0,001 1 11 3 
Hemosiderin-laden macrophages 
0 17 34 0,001 1 6 0 
Mucin lakes 
0 11 27 0,013 1 12 7 
Neoadjuvant CRT +Surgery (Group 1) cT2 cT3 cT4 p 
n 4 15 4  
Fibrosis  
0  0 0 0 
0,330 1  1 1 0 2  2 5 3 
3  1 9 1 
Inflammatory cell infiltration 
0  0 0 0 
0,881 1  2 4 1 2  0 4 2 
3  2 7 1 
Calcification  
0  3 8 1 0,397 1  1 7 3 
Hemosiderin-laden macrophages  
0  3 12 2 0,515 1  1 3 2 
Mucin lakes 
0  3 6 2 0,496 1  1 9 2 
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Although the stromal changes were significantly different between Group 1 
and Group 2, there was not any difference in stromal responses between the 
neoadjuvant CRT received cT2, cT3 and cT4 stages.  
 
CONCLUSION 
 
Neoadjuvant chemoradiation therapy makes a stromal response in tumor bed 
by fibrosis, inflammatory cell infiltration, and accumulation of hemosiderin-
laden macrophages. These changes occur in every tumor bed constantly and 
independently from the clinical/pathological T stage according to our study, 
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